||NCPE Assessment Process Complete
||For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
||Denosumab (Xgeva®) is considered a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting.